All Posts
Five for Friday – CholangioConnect Celebrates its 6th Anniversary and 1000th Match
Home / Blog / [wpbb post:title] It has been said that mentors are people who allow others to see the…
Scientific Update - Development of a Fluorescence-Based Probe to Facilitate Cholangiocarcinoma Resection and Diagnosis
Kelly Butler Some early-stage cholangiocarcinomas can be surgically removed, but detecting microscopic cancer cells remains a significant challenge. Even just…
Five for Friday – Five CCF Programs
Home / Blog / [wpbb post:title] The generosity of donors has assisted us in advancing research in impactful ways and…
Cholangiocarcinoma Foundation Celebrates Major Milestone in Connecting Patients and Caregivers to Mentorship Program
The Cholangiocarcinoma Foundation is celebrating the 1,000th mentor-mentee match and six years of their mentoring program CholangioConnect. CCF, a nonprofit…
Five for Friday – Five ASCO 2023 Highlights
Home / Blog / [wpbb post:title] The American Society of Clinical Oncology (ASCO) meeting took place in Chicago the first…
An Inspiring Visit To California
Along with hundreds of family and friends (many of them talented musicians), I recently had the privilege to participate in…
A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care alone in subjects with advanced solid tumors (BOLSTER)
Study Name A Phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 when added to standard of care (SoC) versus standard of care…
Patty Maxin's CholangioConnect Experience
As I reflect upon the inception of CholangioConnect, a myriad of emotions flood my being. Unequivocally, I recognize that being…
Five for Friday – Five reasons to participate in Moving for the Cure
Home / Blog / [wpbb post:title] Get ready to lace up your sneakers, stretch those muscles, and join us for…
A Phase 2 study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
Study Name A Phase 2 study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or…